The researchers say that, to their knowledge, this is the first demonstration of programmable, site-specific integration of a large DNA payload into T cells in vivo.
InvestorsHub on MSN
HCW Biologics highlights positive findings for CAR-T therapy manufacturing
HCW Biologics Inc. (NASDAQ:HCWB) announced new research published in Science Advances indicating that its compound HCW9206 may improve the production of CAR-T cell therapies. The study was carried out ...
Commercialization ready compound supports a new method of generating highly functional human CAR-T cells for treating infectious diseases and ...
A research team led by Albert Einstein College of Medicine scientists has developed a new strategy to engineer immune cells ...
Dr. John Mellors, who heads the cell therapy discovery team for biotechnology company Galapagos, talks about the innovations the organization is making to improve delivery speed and access to CAR ...
For years, one of the most powerful weapons against certain blood cancers, called CAR-T cell therapy, has required an ...
A research team led by Albert Einstein College of Medicine scientists has developed a new strategy to engineer immune cells that dramatically prolongs their effectiveness after being infused into ...
CAR T-cell therapy is a personalized treatment that uses a patient’s own immune cells to fight cancer, making it effective but unsuitable for mass production, which increases the cost. The complex ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results